Rhythm Biosciences (ASX:RHY) said that its Genetype subsidiary business has secured its first strategic pilot partnership with a leading pathology service provider in Australia, advancing the company's predictive cancer diagnostics technology, according to a Thursday Australian bourse filing.

The partnership brings dedicated resources from both sides to drive innovation in cancer, coronary, and diabetes risk assessment through personalized medicine, expanding patient access to genotyping tests, and setting the stage for wider commercial deployment and increased revenue potential, the filing added.